

# Johannes Ettl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9457682/publications.pdf>

Version: 2024-02-01

67  
papers

3,039  
citations

304743

22  
h-index

161849

54  
g-index

88  
all docs

88  
docs citations

88  
times ranked

4438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study. <i>Cancer Research</i> , 2022, 82, P5-13-08-P5-13-08.	0.9	0
2	Luminal Metastatic Breast Cancer: Current Concepts and Future Approaches. <i>Breast Care</i> , 2021, 16, 99-100.	1.4	2
3	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
4	Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1029.	1.6	5
5	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer – Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
6	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
7	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	3.7	61
8	Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. <i>Breast</i> , 2020, 49, 101-107.	2.2	13
9	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	3.7	6
10	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2 <sup>-</sup> advanced breast cancer (PALOMA-1, TRIO-18). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 419-428.	2.5	73
11	Update Breast Cancer 2020 Part 3 – Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114.	1.8	12
12	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	3.7	19
13	Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	1.8	11
14	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	1.8	4
15	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	2.6	1
16	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	2.5	21
17	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	2.2	34
18	First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1461-1467.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Update Breast Cancer 2020 Part 1 " Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287.	1.8	16
20	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor" positive/human epidermal growth factor receptor 2" negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	5.0	24
21	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician"s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	2.9	24
22	Update Breast Cancer 2020 Part 2 " Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	1.8	12
23	CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, CLO20-052.	4.9	0
24	Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology, 2020, 38, 1018-1018.	1.6	1
25	Update Breast Cancer 2019 Part 4 " Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	1.8	18
26	Update Breast Cancer 2019 Part 5 " Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	1.8	16
27	MRI based neuroanatomical segmentation in breast cancer patients: leptomeningeal carcinomatosis vs. oligometastatic brain disease vs. multimetastatic brain disease. Radiation Oncology, 2019, 14, 170.	2.7	6
28	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2" Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	3.7	49
29	Update Breast Cancer 2019 Part 1 " Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 256-267.	1.8	17
30	Update Breast Cancer 2019 Part 3 " Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482.	1.8	26
31	Update Breast Cancer 2019 Part 2 " Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 268-280.	1.8	21
32	Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors. Breast Care, 2019, 14, 86-92.	1.4	28
33	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	2.0	16
34	Translational Highlights in Breast and Ovarian Cancer 2019 " Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	1.8	11
35	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers, 2019, 11, 10.	3.7	43
36	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	2.5	40

#	ARTICLE	IF	CITATIONS
37	PROoutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer. <i>Annals of Palliative Medicine</i> , 2019, 8, 104-111.	1.2	75
38	ABC4 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2018, 13, 48-58.	1.4	7
39	Update Breast Cancer 2018 (Part 1) â€œ Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
40	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 271-280.	1.4	33
41	Update Breast Cancer 2018 (Part 2) â€œ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
42	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€œ Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
43	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
44	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	1.8	3
45	Update Breast Cancer 2018 (Part 3) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	1.8	8
46	PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. <i>EJNMMI Research</i> , 2018, 8, 90.	2.5	31
47	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€œ a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	1.8	3
48	Molecular Tumor Boards. <i>Breast Care</i> , 2018, 13, 137-139.	1.4	2
49	Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial. <i>Breast Cancer</i> , 2017, 24, 319-325.	2.9	8
50	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245.	1.7	42
51	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
52	The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 661-668.	2.4	9
53	The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial. <i>Clinical Breast Cancer</i> , 2017, 17, 100-106.	2.4	27
54	Update Breast Cancer 2017 â€œ Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19

#	ARTICLE	IF	CITATIONS
55	The Predictive Value of <i>PITX2</i> DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. <i>Disease Markers</i> , 2017, 2017, 1-14.	1.3	18
56	Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. <i>PLoS ONE</i> , 2017, 12, e0183917.	2.5	15
57	Polyurethane versus silicone catheters for central venous port devices implanted at the forearm. <i>European Journal of Cancer</i> , 2016, 59, 113-124.	2.8	62
58	ABC3 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2016, 11, 61-70.	1.4	8
59	Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer. <i>Breast Care</i> , 2016, 11, 174-176.	1.4	10
60	Mechanic and surface properties of central-venous port catheters after removal: A comparison of polyurethane and silicon rubber materials. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2016, 64, 281-291.	3.1	38
61	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
62	First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. <i>Journal of Nuclear Medicine</i> , 2016, 57, 741-746.	5.0	109
63	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 25-35.	10.7	1,574
64	Risk factors for the incidence of breast cancer after prophylactic mastectomy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12545-e12545.	1.6	0
65	Iyengar yoga compared to exercise in women with stage I-III breast cancer: Feasibility of therapeutic interventions during adjuvant cytotoxic or endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20623-e20623.	1.6	2
66	Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 556-556.	1.6	2
67	Nipple-sparing subcutaneous mastectomy (NSSM) as dual-plane prosthetic reconstruction using the modified Wise pattern mastectomy, fasciocutaneous flap, and titan-polypropylen-mesh-interponation in women with macromastia.. <i>Journal of Clinical Oncology</i> , 2012, 30, 156-156.	1.6	0